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Abstract
Background: Authors of recent meta-analyses have reported that prolonged glucocorticoid treatment is associated
with significant improvements in patients with severe pneumonia or acute respiratory distress syndrome (ARDS) of
multifactorial etiology. A prospective randomized trial limited to patients with sepsis-associated ARDS is lacking. The
objective of our study was to evaluate the efficacy of hydrocortisone treatment in sepsis-associated ARDS.
Methods: In this double-blind, single-center (Siriraj Hospital, Bangkok), randomized, placebo-controlled trial, we
recruited adult patients with severe sepsis within 12 h of their meeting ARDS criteria. Patients were randomly assigned
(1:1 ratio) to receive either hydrocortisone 50 mg every 6 h or placebo. The primary endpoint was 28-day all-cause
mortality; secondary endpoints included survival without organ support on day 28.
Results: Over the course of 4 years, 197 patients were randomized to either hydrocortisone (n = 98) or placebo (n = 99)
and were included in this intention-to-treat analysis. The treatment group had significant improvement in the ratio of
partial pressure of oxygen in arterial blood to fraction of inspired oxygen and lung injury score (p = 0.01), and similar
timing to removal of vital organ support (HR 0.74, 95 % CI 0.51–1.07; p = 0.107). After adjustment for significant covariates,
day 28 survival was similar for the whole group (HR 0.80, 95 % CI 0.46–1.41; p = 0.44) and for the larger subgroup (n = 126)
with Acute Physiology and Chronic Health Evaluation II score <25 (HR 0.57, 95 % CI 0.24–1.36; p= 0.20). With the exception
of hyperglycemia (80.6 % vs. 67.7 %; p = 0.04), the rate of adverse events was similar. Hyperglycemia had no
impact on outcome.
Conclusions: In sepsis-associated ARDS, hydrocortisone treatment was associated with a significant
improvement in pulmonary physiology, but without a significant survival benefit.
Trial registration: ClinicalTrials.gov identifier NCT01284452. Registered on 18 January 2011.
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Background
Acute respiratory distress syndrome (ARDS) is a second-
ary disease that follows—usually within 6–48 h—a pri-
mary disease of multifactorial etiology (most frequently
pneumonia and extrapulmonary sepsis [1]) associated
with severe systemic inflammation. Inflammatory media-
tors released into the systemic circulation (systemic
inflammation) from the site of infection reach the broad
pulmonary capillary surface, producing severe and
diffuse inflammatory exudate of the pulmonary lobules
and resulting in hypoxemic respiratory failure [2]. In
addition to the lung, systemic inflammation involves
other vital organs, particularly the cardiovascular and renal
systems. In ARDS, baseline plasma inflammatory cytokine
levels are associated with a significantly increased risk of
death after adjustment for tidal volume (6 ml/kg vs. 12 ml/
kg) and severity of illness [3], and higher inflammatory
cytokine levels are found in the largest subgroup of sepsis-
associated ARDS [3]. Sepsis-associated ARDS, in compari-
son with sepsis without ARDS [4] or non-sepsis-related
ARDS [1, 5], is associated with significantly higher morbid-
ity and higher (up to 60 % [4, 6]) mortality.
In sepsis and ARDS, systemic inflammation is acti-
vated by the nuclear factor-κB (NF-κB) signaling system
and downregulated by activated glucocorticoid receptor
α (GRα) [7]. In these patients, inadequate (endogenous
glucocorticoid-activated) GRα-mediated downregulation
of proinflammatory transcription factor NF-κB in circu-
lating and tissue cells leads to higher initial levels and
persistent elevation over time of plasma and bronchoal-
veolar lavage markers of inflammation, hemostasis, and
tissue repair [7]. Inadequate intracellular GRα-mediated
anti-inflammatory activity for the severity of the patient’s
illness was recently termed critical illness-related
corticosteroid insufficiency (CIRCI) [8]. Experimental
[9] and clinical research [7] shows that CIRCI can be im-
proved with quantitatively and temporally adequate gluco-
corticoid administration, and a new meta-analysis provides
support for its use in ARDS of multifactorial etiology [10].
Despite the high prevalence and mortality of sepsis-
associated ARDS, a prospective randomized controlled
trial (RCT) investigating glucocorticoid treatment is lack-
ing. We conducted this RCT to test the hypothesis that
the anti-inflammatory action of 7 days of hydrocortisone
treatment would result in accelerated disease resolution
and lower mortality. The primary outcome was 28-day all-
cause mortality; secondary endpoints included 28-day sur-
vival without organ support and 60-day mortality.
Methods
Study design
We conducted an investigator-initiated, single-center,
double-blind, randomized, parallel-groups, placebo-
controlled trial between December 2010 and December
2014 in the medical intensive care unit of Siriraj
Hospital, Bangkok, Thailand. This trial is registered with
ClinicalTrials.gov (NCT01284452). The study was con-
ducted in accordance with the original protocol. The full
study protocol is available by contacting the principal
investigator.
Patients
We prospectively screened patients aged 18 years or
older meeting the criteria for severe sepsis or septic
shock [11]. Patients with severe sepsis or septic shock
receiving mechanical ventilation (MV) for hypoxemic
respiratory failure were eligible if, within 12 h of study
entry, they met the diagnostic criteria for acute lung
injury-ARDS according to the American-European
Consensus definition [12], as later reclassified on the
basis of the 2012 Berlin criteria for the diagnosis of
ARDS [13]. Informed consent was obtained from the pa-
tients or their legally authorized representatives prior to
enrollment. Exclusion criteria included moribund state
(i.e., not expected to live more than 24 h), advanced
malignancy with life expectancy <6 months, pregnancy,
immunosuppressive therapy, underlying disease requir-
ing long-term glucocorticoid treatment within the last
6 months or short-term glucocorticoid treatment within
the past 4 weeks, and difficult-to-control diabetes.
Randomization and study intervention
The coinvestigators (CP, WM, VV) evaluated patients
for eligibility, obtained informed consent, and enrolled
the participants. After inclusion, patients were randomly
assigned without restriction in a 1:1 ratio (hydrocorti-
sone to placebo) according to a computer-generated
randomization table derived from www.randomization.com
by the principal investigator, who had no role in patient
management. A research nurse not otherwise involved in
the study prepared both the study drug and placebo. The at-
tending physicians, nursing care teams, research in-
vestigators, and participants and their family members
were blinded to treatment allocation. Hydrocortisone
was given daily as an intravenous bolus (50 mg in
10 ml of normal saline) every 6 h for 7 days. The
control group received a comparable volume of nor-
mal saline on the same time schedule. Fluid resuscita-
tion and vasopressor treatment were administered
according to the Surviving Sepsis Campaign guide-
lines [14, 15]. Clinicians were asked to comply with
the ARDS Network guidelines on low tidal volume
and positive end-expiratory pressure [16]. The at-
tending physician managed adjustments of ventilator
settings, antibiotic selection, nutritional support, gly-
cemic control, and the initiation of renal replace-
ment therapy.
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Study endpoints and data collection
This RCT tested the hypothesis that the addition of
hydrocortisone treatment to standard care would
result in accelerated disease resolution and lower
mortality. The primary endpoint of the study was
all-cause mortality at study day 28. Secondary out-
comes included (1) patients alive without organ sup-
port (ventilator, renal replacement therapy, and
vasopressors) on day 28, (2) MV-free days up to day
28, (3) vasopressor (dopamine, norepinephrine, or
adrenaline)-free days up to day 28 (free days to day
28 for patients who died before or on study day 28
was set to 0), and (4) mortality at study day 60. Re-
turn to MV after initial successful (off or at least
48 h) extubation was included in the total duration
of MV until study day 28.
Baseline data collected included, age, sex, comorbidi-
ties, sepsis severity, source of infection, Acute Physiology
and Chronic Health Evaluation (APACHE) II score
[17], Sequential Organ Failure Assessment score [18],
and Lung Injury Score (LIS) [19]. Progression of
ARDS was monitored with longitudinal measurements
of the LIS (days 0–7 and 14) [19]. For adverse events,
we monitored for nosocomial infections, hypergly-
cemia (glucose >150 mg/dl), and gastrointestinal
bleeding until study day 28.
Statistical analysis
The study protocol stated that the number needed to
enroll in this study was calculated by assuming that
the 28-day mortality of severe sepsis or septic shock-
associated ARDS was 60 % [4, 6]. To detect a 20 %
Fig. 1 Flow diagram of the progress of the trial
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absolute mortality reduction, enrollment of at least
194 patients was required to provide study power of
80 % and a two-sided alpha error of 0.05. There was
no planned interim analysis.
The study was analyzed on an intention-to-treat
basis. The continuous variables were compared at two
or more levels of a categorical factor of interest using
the Wilcoxon-Mann-Whitney test, which is a non-
parametric counterpart of the two-samples t test. The
categorical variables were compared with the use of
the chi-square test or Fisher’s exact test, when suit-
able. The primary outcome was evaluated by chi-
square test, and the secondary outcomes were
analyzed by chi-square test and Wilcoxon-Mann-






Age, years 64.5 ± 17.3 64.3 ± 16.0 0.76
Male sex, n (%) 50 (51) 51 (51.5) 1.0
APACHE II scoreb 21.7 ± 5.7 21.9 ± 5.7 0.79
SOFA scorec 10.9 ± 3.5 10.8 ± 3.6 0.91
Lung Injury Score,d
mean ± SE
2.2 ± 0.9 2.2 ± 1.0 0.7
Vasopressor-dependent
shock, n (%)
78 (79.6) 76 (76.8) 0.55
Lactate, mmol/L 3.9 ± 2.2 4.0 ± 2.5 0.95
Lactate >2 mmol/L, n (%) 85 (86.7) 82 (82.7) 0.55
Mild ARDS: PaO2/FiO2
201–300,e n (%)








12 (12.2) 18 (18.4) 0.32
Tidal volume, ml/kg of
predicted body weight
7.06 ± 1.12 7.57 ± 1.34 0.04
Tidal volume >8 ml/kg of
predicted body weight, n (%)
35 (35.4) 41 (41.8) 0.38
Positive end-expiratory
pressure, cmH2O
7.3 ± 3.0 6.8 ± 2.5 0.59
PaO2/FiO2, mmHg, mean ± SE 175.4 ± 6.9 172.4 ± 6.7 0.87
Source of infection, n (%)
Pneumonia 49 (50) 51 (52) 0.89
Urinary tract infection 18 (18.4) 19 (19.2) 1.0
Skin and soft tissue infection 15 (15.3) 12 (12.1) 0.54
Intra-abdominal infection 15 (15.3) 7 (7.1) 0.07
Hemoculture-positive 28 (28.6) 28 (28.3) 1.0
Number of comorbidities,
median (range)
2 (0–5) 2 (0–5) 1.0
Hypertension 44 (44.9) 43 (43.4) 0.89
Diabetes mellitus 45 (45.9) 37 (37.4) 0.25
Coronary artery disease 18 (18.4) 17 (17.2) 0.85
Stroke 21 (21.4) 14 (14.1) 0.2
Chronic kidney disease 12 (12.2) 12 (12.1) 1.0
Chronic lung disease 11 (11.2) 11 (11.1) 1.0
Cancer and/or
immunosuppression
18 (18.4) 26 (26.3) 0.23
Abbreviations: APACHE II Acute Physiology and Chronic Health Evaluation II,
ARDS Acute respiratory distress syndrome, FiO2 Fraction of inspired oxygen,
PaO2 Partial pressure of oxygen in arterial blood, SOFA Sequential Organ
Failure Assessment
Unless specified otherwise, data are reported as mean ± SD
aFisher’s exact test and the Wilcoxon-Mann-Whitney test were used for categorical
and continuous variables, respectively
bAPACHE II score, a severity-determining score, ranges from 0 to 71. The
higher scores represent more severe disease
cSOFA score ranges from 0 to 24. The higher scores represent more organ failure
dThe Lung Injury Score ranges from 0 to 4. Scores of 0.1–2.5 indicate mild to
moderate lung injury; scores >2.5 indicate severe lung injury
eDiagnosis of ARDS according to the Berlin Definition 2012
Fig. 2 a Changes in ratio of partial pressure of oxygen in arterial blood
fraction of inspired oxygen (PaO2/FiO2) over the course of 7 days and
on day 14. In comparison with the placebo group, the hydrocortisone
group had a significantly higher PaO2/FiO2 ratio by day 3 (p = 0.03) and
throughout the observation period. b Changes in Lung Injury Score
over the course of 7 days and on day 14. In comparison with
the placebo group, the hydrocortisone group had a significantly
lower Lung Injury Score by day 3 (p = 0.003) and throughout the
observation period
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Whitney test. For the survival analysis, time to an event of
interest was calculated from the date of randomization to
the date of the event. Patients who did not experience the
event were censored at their last-follow up date or at a
specified cutoff date such as day 28 or day 60. Survival dis-
tributions were estimated using the Kaplan-Meier method
and compared by log-rank test.
We also compared the distribution of the time to
event, where an event was defined as death or removal
of vital organ support independently, by the following
prespecified variables: age (≤65 years or >65 years),
APACHE II score (<25 or ≥25), LIS (<2.5 or ≥2.5), sepsis
severity (absence of shock or vasopressor-dependent
shock), ARDS severity (mild or moderate to severe),
source of infection (pneumonia or extrapulmonary), and
number of comorbidities (two or fewer or three or
more). Association of the survival likelihood of a given
event (death or removal from organ support, independ-
ently) with a set of variables was estimated using a Cox
proportional hazards model in which treatment was kept
in such multiple regression models regardless of its signifi-
cance. To describe and compare the profiles of longitu-
dinal variables of interest, a random coefficient modeling
framework was used in which time was the primary pre-
dictor and time × treatment interaction indicated the
treatment differences in the profiles under investigation. A
p value <0.05 was considered statistically significant for all
comparisons. SAS® version 9.4 software (SAS Institute,
Cary, NC, USA) was used to conduct all of the analyses.
Results
Figure 1 shows progress through the phases of the trial.
The trial was stopped when target recruitment was
achieved. Of the 206 randomized patients, 9 (6 hydro-
cortisone, 3 placebo) withdrew consent after randomization
and were excluded from analysis. Two hundred thirteen pa-
tients were excluded because they were already receiving
hydrocortisone for hemodynamic stabilization of refractory
septic shock on high-dose vasopressors. The intention-to-
treat analysis included 197 patients (98 hydrocortisone, 99
placebo). For the primary endpoint, none of the patients in
the intention-to-treat analysis were lost to follow-up. Unless
specified otherwise, comparison between groups is
reported as hydrocortisone vs. placebo. The mean
time (in hours) from meeting severe sepsis criteria to
randomization was similar between groups (11.9 ± 7.9 h
vs.14.0 ± 10.2 h; p = 0.21).
The baseline characteristics of each group at study
entry were similar (Table 1). Most patients had
vasopressor-dependent shock (n = 154; all but 7 with
a lactate level >2 mmol/L) [20] and met criteria for
moderate to severe ARDS (n = 135). Lactate level
(3.9 ± 2.2 mmol/L vs. 4.0 ± 2.5 mmol/L; p = 0.95) and
distribution of patients with fluid-responsive shock
was similar (6.1 % vs. 4.0 %; p = 0.55). The most
common comorbidities were hypertension and dia-
betes mellitus. The leading cause of sepsis was pneu-
monia; overall, bacteremia was present in 28 %.
During treatment intervention, the treated group had
significant improvement in gas exchange and LIS
(Fig. 2), as well as a similar rate of extubation
(43.3 % vs. 31.6 %; p = 0.11). On study day 7 (mean
± SE), the ratio of partial pressure of oxygen in ar-
terial blood to fraction of inspired oxygen (PaO2/
FiO2) was 319.1 ± 9.7 vs. 266.3 ± 11.7 (p = 0.001), and
the LIS was 1.1 ± 0.1 vs. 1.4 ± 0.1 (p = 0.01). These









Mortality at 28 days, n (%) 22 (22.5) 27 (27.3) 0.82 (0.50–1.34) 0.51
Secondary outcomes
Mortality at 60 days, n (%) 34 (34.7) 40 (40.4) 0.86 (0.60–1.23) 0.46
Duration of mechanical ventilation up to day 28, days 11.8 ± 7.8 13.9 ± 9.0 0.17
Mechanical ventilation-free days to day 28 12.0 ± 9.7 9.7 ± 10.0 0.17
Duration of vasopressor treatment,b days 4.8 ± 3.0 6.8 ± 5.7 0.16
Renal replacement therapy, n (%) 22 (22.4) 22 (22.2) 1.01 (0.86–1.16) 1.00
Duration of renal replacement therapy dependent,c days 8.1 ± 6.6 8.2 ± 5.2 0.94
Alive on day 28 without organ support, n (%) 64 (65.3) 55 (55.6) 1.18 (0.94–1.48) 0.19
Organ support-free days to day 28d 11.9 ± 9.7 9.5 ± 9.8 0.13
Unless specified otherwise, data are reported as mean ± SD
aFor continuous variables, p values were calculated using the Wilcoxon-Mann-Whitney test
bData calculated for the patients who received vasopressors
cData calculated for the patients who received renal replacement therapy
dOrgan support includes the use of mechanical ventilation, vasopressors, or renal replacement therapy
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positive effects persisted at day 14 (last measure-
ment), 7 days after removal of the study drug. In
addition, the random coefficients models using the
longitudinal data for PaO2/FiO2 and LIS revealed
that the treatment arm had significantly improved
profiles over time (p = 0.002).
Data for the primary and secondary outcomes are
shown in Table 2. By day 28, the treated group had a
nonsignificant reduction in duration (days) of MV
(10.4 ± 9.4 days vs. 12.4 ± 11.0 days; p = 0.16) and
vasopressor support (4.8 ± 3.0 days vs. 6.8 ± 5.7 days;
p = 0.16), as well as a nonsignificant increase in pa-
tients alive on day 28 without organ support. To
evaluate time to survival without organ support at
28 days, a Kaplan-Meier curve was plotted (Fig. 3a).
After adjustment by Cox regression analysis for two
covariates found to be significant in the multivariate
survival model (Table 3), the hydrocortisone cohort
showed an HR of 0.74 (95 % CI 0.51–1.07; p = 0.107).
Unadjusted mortality at day 28 and day 60 was similar
(Table 2). Subgroup analysis for the relative risk of death
at days 28 and 60 is shown in Table 4. After adjustment
by Cox regression analysis for covariates we found sig-
nificant in the multivariate survival model (Table 3), the
HRs for death at days 28 and 60 were 0.80 (95 % CI
0.46–1.41; p = 0.44) and 0.81 (95 % 0.51–1.28; p = 0.37),
respectively. The APACHE II score was the most
significant (p = 0.001) variable detected in the survival
models (Table 3). A Kaplan-Meier curve adjusted for
vasopressor-dependent shock and LIS at study entry was
generated for the subgroups of patients with APACHE II
score <25 vs. ≥25 by treatment (Fig. 3b). After adjustment
for the presence of vasopressor-dependent shock and LIS,
in the largest subgroup with APACHE II score <25
(n = 126), the HR for probability of survival at 28 days was
0.57 (95 % CI 0.24–1.36, p = 0.20), and at 60 days it was
0.69 (95 % CI 0.36–1.31; p = 0.25). In the subgroup with
APACHE II score ≥25 (n = 71), the HR for probability of
survival at 28 days was 1.05 (95 % CI 0.49–2.23; p = 0.60),
and at 60 days it was 0.97 (95 % CI 0.50–1.88; p = 0.92).
With the exception of hyperglycemia (80.6 % vs.
67.7 %; p = 0.04), the rate of adverse events was simi-
lar (Table 5). The incidence of hyperglycemia in
patients with (80 % vs. 70 %; p = 0.45) and without
(81 % vs. 66 %; p = 0.09) underlying diabetes was
similar. Neither diabetes nor hyperglycemia (at study
entry or after randomization) had an impact on sur-
vival (data not shown).
Discussion
This is the first prospective trial investigating a 7-day
course of low-dose hydrocortisone treatment in patients
with sepsis-associated early ARDS. Hydrocortisone
treatment was associated with rapid and sustained
improvement in pulmonary physiology and a nonsig-
nificant increase (65.3 % vs. 55.6 %; p = 0.19) in
patients alive on day 28 without organ support. The
significant physiological improvements did not trans-
late into an overall survival benefit for the whole
group (HR 0.80, 95 % CI 0.46–1.41; p = 0.44), how-
ever, and for the largest subgroup of patients with
APACHE II score <25 (HR 0.57, 95 % CI 0.24–1.36;
p = 0.20). Importantly, in agreement with the literature
on sepsis [21] and ARDS [10], we did not find an
increased risk of complications, with the exception of
hyperglycemia, and hyperglycemia did not affect
Fig. 3 a Kaplan-Meier estimate of time to removal of organ support
by treatment arm after adjustment by Cox regression analysis for
Acute Physiology and Chronic Health Evaluation II (APACHE II) score
and Lung Injury Score. Continuous line corresponds to the placebo
group, and dashed line corresponds to the hydrocortisone group. b
Kaplan-Meier curve illustrates the probability of survival at 60 days
based on APACHE II score <25 vs. ≥25. Continuous line corresponds
to the subgroup with APACHE II score <25 (blue = hydrocortisone,
red = placebo). Dashed line corresponds to the subgroup with
APACHE score ≥25 (blue = hydrocortisone, red = placebo). After
adjustment for the presence of vasopressor-dependent shock and
Lung Injury Score, in the subgroup with APACHE score <25 (n = 126),
the HR for probability of survival at 28 days was 0.57 (95 % CI 0.24–1.36;
p= 0.20), and at 60 days it was 0.69 (95 % CI 0.36–1.31; p= 0.25). In the
subgroup with APACHE II score ≥25 (n= 71), the HR for probability of
survival at 28 days was 1.05 (95 % CI 0.49–2.23; p= 0.60), and at 60 days
it was 0.97 (95 % CI 0.50–1.88; p= 0.92)
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outcome. Our findings are placed in the context of
the limitations of the trial and the updated literature.
Our study has several limitations. First, and most im-
portant, our study was significantly underpowered by
the recruitment of patients with less severe illness and
lower mortality. While the original sample size calcula-
tion was based on a control mortality of 60 %, originat-
ing from the findings of the largest prior trial [6], our
control 28-day mortality was almost half that and similar
to the most recent report [5]. This is partly attributable
to two main factors: (1) exclusion of a large number of
patients who, during the screening process, were already
receiving hydrocortisone treatment for refractory septic
shock [14]; and (2) improved outcome as a result of
implementing the international guidelines of the Surviv-
ing Sepsis Campaign [14]. In comparison with prior
RCTs, our trial differs by not including longitudinal
measurements of systemic inflammatory response syn-
drome parameters or markers of systemic inflammation
[6, 22–27] and an assessment of adrenal function [6, 26].
Seven RCTs published in the English language
investigated prolonged glucocorticoid treatment in
ARDS [6, 22–27]. In each trial, glucocorticoid treatment
was associated with a significant reduction in markers of
systemic inflammation (inflammatory cytokines and/or
C-reactive protein levels) and improvement in lung
function. Three trials investigated hydrocortisone treat-
ment in sepsis [22, 23] or septic shock-associated ARDS
[6]. The largest study [6] is a post hoc analysis of 177 pa-
tients with ARDS from a trial of vasopressor-dependent
septic shock investigating hydrocortisone (dosage similar
to our trial) and fludrocortisone (50 μg daily) treatment
[28]. In the largest trial [6], among those randomized to
receive the active drug, the larger subgroup (n = 129) of
nonresponders to a short corticotropin test, contrary to
responders (n = 48), had more days alive and off a
mechanical ventilator (5.6 ± 8.8 days vs. 2.6 ±
6.6 days; p = 0.006) and improved survival (47 % vs.
25 %; p = 0.021). Two other trials [22, 23] of
patients with severe community-acquired pneumonia
included 94 patients on MV with early ARDS (16 %
with shock). In both trials [22, 23], a hydrocortisone
bolus (200 mg) followed by an infusion (240–300 mg/
24 h) was associated with a significant reduction in
duration of MV; one research group reported
improved survival [22].
Four trials investigated prolonged methylprednisolone
treatment in early [26, 27] and late [24, 25] ARDS and
Table 3 Univariable and multivariable survival models for time to organ support removal and overall survival on day 28







Hydrocortisone vs. placebo 1.35 (0.93–1.92) 0.11 0.82 (0.47–1.43) 0.49
APACHE II score: <25 vs. ≥25 1.46 (0.97–2.18) 0.066 0.39 (0.22–0.69) 0.0011
Lung Injury Score: <2.5 vs. ≥2.5 1.57 (1.08–2.30) 0.019 0.71 (0.40–1.24) 0.23
Vasopressor-dependent shock:
absent vs. present
1.63 (1.09–2.45) 0.018 0.46 (0.19–1.07) 0.071
ARDS severity: mild vs. moderate
to severe
0.79 (0.54–1.16) 0.23 1.54 (0.81–2.96) 0.19
Number of comorbidities: ≤2 vs. >2 0.95 (0.64–1.40) 0.79 1.25 (0.71–2.19) 0.44
Source of infection: pneumonia vs.
extrapulmonary source
1.09 (0.64–1.85) 0.75 0.90 (0.51–1.58) 0.71
Age: ≤65 years vs. >65 years 1.40 (0.97–2.02) 0.071 1.33 (0.76–2.35) 0.32
Diabetes mellitus: no vs. yes 0.95 (0.64–1.40) 0.79 1.66 (0.84–3.28) 0.18
Hyperglycemia: no vs. yes 0.97 (0.66–1.42) 0.8 1.37 (0.67–2.80) 0.45
Multivariable models
Hydrocortisone vs. placebo 1.35 (0.93–1.96) 0.107 0.80 (0.46–1.41) 0.44
APACHE II score: <25 vs. ≥25 Not included in multivariable model 0.42 (0.24–0.75) 0.003
Vasopressor-dependent shock:
absent vs. present
1.562 (1.04–2.35) 0.032 0.55 (0.23–1.29) 0.17a
Lung Injury Score: <2.5 vs. ≥2.5 1.633 (1.11–2.4) 0.012 Not included in multivariable model
APACHE II Acute Physiology and Chronic Health Evaluation II, ARDS Acute respiratory distress syndrome
Multivariable survival models for time to survival on day 60 were significant for APACHE II score (HR 0.56, 95 % CI 0.35–0.89; p = 0.015) and Lung Injury Score (HR
0.62, 95 % CI 0.39–0.99; p = 0.045), and they showed a nonsignificant favorable trend for hydrocortisone vs. placebo (HR 0.81, 95 % CI 0.51–1.28; p = 0.37)
aThis variable was included because it was significant in the day 60 survival model
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Table 4 Subgroup analysis of the risk of death in the hydrocortisone and placebo groups at days 28 and 60
Day 28 Day 60
Subgroup Hydrocortisone
(n = 98)












Age ≤65 years, n/total (%) 12/50 (24.0) 16/50 (32.0) 0.75 (0.40–1.42) 0.50 18/50 (36.0) 19/50 (38.0) 0.95 (0.57–1.58) 1.00
Age >65 years, n/total (%) 10/48 (20.8) 11/49 (22.5) 0.93 (0.43–1.98) 1.00 16/48 (33.3) 21/49 (42.9) 0.78 (0.47–1.3) 0.40
APACHE II score
APACHE II score <25, n/total (%) 8/61 (13.1) 14/65 (21.5) 0.61 (0.27–1.35) 0.25 16/61 (26.2) 22/65 (33.8) 0.61 (0.27–1.35) 0.44
APACHE II score≥ 25, n/total (%) 14/37 (37.8) 13/34 (38.2) 0.99 (0.55–1.79) 1.00 18/37 (48.7) 18/34 (52.9) 0.92 (0.58–1.45) 0.81
Lung injury score
Lung injury score < 2.5, n/total (%) 11/54 (20.4) 13/58 (22.4) 0.91 (0.45–1.85) 0.82 16/54 (29.6) 17/58 (29.3) 1.01 (0.60–1.79) 1.00
Lung injury score ≥ 2.5, n/total (%) 11/44 (25) 13/40 (32.5) 0.77 (0.39–0.52) 0.48 18/44 (40.9) 22/40 (55.0) 0.74 (0.47–1.17) 0.27
Sepsis severity
Severe sepsis without shock, n/total (%) 3/20 (15.0) 3/23 (13.0) 1.15 (0.26–5.07) 1.00 4/20 (20.0) 5/23 (21.7) 0.92 (0.29–2.97) 1.00
Vasopressor dependent shock, n/total (%) 19/78 (24.4) 24/76 (31.6) 0.77 (0.46–1.29) 0.37 30/78 (38.5) 35/76 (46.1) 0.84 (0.58–1.21) 0.41
ARDS severity
Mild ARDS, n/total (%) 5/30 (16.7) 7/32 (21.9) 0.76 (0.27–2.14) 0.75 9/30 (30.0) 10/32 (31.3) 0.96 (0.45–2.03) 1.00
Moderate to severe ARDS, n/total (%) 17/68 (25.0) 20/67 (29.9) 0.84 (0.48–1.45) 0.57 25/68 (36.8) 30/67 (44.8) 0.82 (0.55–1.24) 0.38
Source of infection
Pneumonia, n/total (%) 11/49 (22.5) 13/51 (25.5) 0.88 (0.44–1.77) 0.82 18/49 (36.7) 19/51 (37.3) 0.99 (0.59–1.64) 1.00
Others, n/total (%) 1/10 (10.0) 6/18 (33.3) 0.30 (0.04–2.15) 0.36 1/10 (10.0) 7/18 (38.9) 0.26 (0.04–1.80) 0.19
Number of comorbidities
≤ 2 comorbidities, n/total (%) 18/67 (26.9) 22/77 (28.6) 0.94 (0.55–1.60) 0.85 25/67 (37.3) 30/77 (39.0) 0.96 (0.63–1.45) 0.87
≥ 3 comorbidities, n/total (%) 4/31 (12.9) 5/22 (22.7) 0.57 (0.17–1.88) 0.46 9/31 (29.0) 10/2 (45.5) 0.64 (0.31–1.31) 0.26









were the subject of a recent individual patient data (IPD)
meta-analysis (n = 322) [10]. By study day 28, the meth-
ylprednisolone group had fewer patients dying while on
MV (12 % vs. 29 %; p < 0.001) and more patients suc-
cessfully extubated (80 % vs. 50 %; p < 0.001); hospital
mortality was decreased (20 % vs. 33 %; p = 0.006).
Importantly, each trial [24–27] consistently reported a
9- to 10-day reduction in duration of MV during meth-
ylprednisolone administration (Table S3 supplementary
material in [10]). All but one trial [25] incorporated slow
tapering of the study drug after extubation; lack of slow
tapering contributed to increased return to MV [25].
Our trial is a single-center RCT, which may raise con-
cerns regarding the generalization of the results based
on participants’ characteristics and the intervention
tested. In comparison with our study, severity of illness
scores and LISs were higher in five RCTs [6, 24–27] and
similar in two RCTs [22, 23]. Fundamental variables of
the treatment protocol that may significantly affect
overall response to glucocorticoid treatment in ARDS
include study drug, dosage, and duration of administra-
tion, including tapering [7]. Our treatment intervention
was comparable to the one investigated in the two RCTs
with lower severity of illness [22, 23] and differed from
the other five RCTs by study drug (hydrocortisone vs.
hydrocortisone plus fludrocortisone [6] or methylpred-
nisolone [24–27]), duration of treatment (7 days vs.
14–28 days [24–27]), and tapering (lack of tapering
vs. slow tapering [24, 26, 27]).
In the past exogenous glucocorticoids were thought to
be qualitatively indistinguishable because they act via the
same receptor, but qualitative differences have been
discovered, and one glucocorticoid cannot be simply
replaced by another [29]. In reference to the RCTs
described above [6, 24–27], hydrocortisone has (1) less
anti-inflammatory potency when it is not combined with
fludrocortisone (a drug with both mineralocorticoid and
glucocorticoid activities) and (2) lesser direct inhibitory
NF-κB activity than methylprednisolone (half-maximal
inhibitory concentration for NF-κB inhibition 16 and
2.8, respectively) [30]. Methylprednisolone, because of
its greater penetration in lung tissue and longer resi-
dence time [31], is the most frequently used intravenous
glucocorticoid for the treatment of severe acute inflam-
matory lung diseases [32].
New understanding of the central role played by glu-
cocorticoids in resolution of inflammation and restor-
ation of tissue homeostasis [33] provides support for
longer duration of treatment incorporating slow tapering
(up to 4 weeks). A recent IPD meta-analysis demon-
strates that lack of glucocorticoid tapering after extuba-
tion of patients with ARDS is frequently associated with
clinical deterioration and return to MV [10]. Similarly,
researchers in a comparison study of two concurrent
RCTs—hydrocortisone 7-day infusion vs. prolonged
methylprednisolone—reported that removing hydrocor-
tisone without tapering led to a rebound of systemic in-
flammation with worsening organ dysfunction requiring
reintubation [34]. In our study, we did not measure
markers of inflammation and cannot comment on the
presence of rebound inflammation. After completion of
study treatment, however, the hydrocortisone group con-
tinued to demonstrate improved gas exchange and LIS,
and the two groups had a similar rate of reintubation by
day 28. While these findings may suggest that a clinically
significant rebound effect is less likely, most patients
(n = 55) had hydrocortisone treatment discontinued
prior to extubation, masking a possible rebound.
Our trial does not confirm the benefits reported on
the basis of prior RCTs for reduction in duration of
MV and intensive care unit stay [22–27] or survival
[22–24, 26, 27]. Our study is underpowered for the
exploratory analysis to demonstrate a survival benefit
in patients with APACHE II scores <25. It is likely
that this cohort had a lesser degree of systemic inflam-
mation than patients with APACHE II scores ≥25. Lacking
measurement of markers of systemic inflammation over
time, we cannot comment on whether our treatment
protocol was less effective in achieving a significant anti-
inflammatory effect in those with APACHE II scores ≥25.
Conclusions
In sepsis-associated ARDS, early administration of
hydrocortisone 50 mg intravenously every 6 h for
7 days was safe and associated with improved lung
function without a significant survival benefit. Our
study is underpowered for the exploratory analysis to
demonstrate a survival benefit in patients with
APACHE II scores <25.






Nosocomial infection 17 (17.3) 19 (19.2) 0.74
Lung infection 10 (10.2) 12 (12.1) 0.67
Catheter-related
bloodstream infection
3 (3.1) 5 (5.1) 0.72a
Urinary tract infection 3 (3.1) 2 (2) 0.68a
Other nosocomial
infection
1 (1) 3 (3) 0.62a
Hyperglycemia
(glucose >150 mg/dl)
79 (80.6) 67 (67.7) 0.038
New-onset atrial fibrillation 3 (3.1) 5 (5.1) 0.72
Reintubation within
28 days
6 (6.1) 7 (7.2) 0.78
Gastrointestinal bleeding 3 (3.1) 4 (4) 1.00
aFisher’s exact test p values due to small cell counts
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Key messages
 Pneumonia and extrapulmonary sepsis are the
leading causes of ARDS. Sepsis-associated ARDS, in
comparison with sepsis without ARDS or non-sepsis-
related ARDS, is associated with higher morbidity and
mortality.
 Despite the high prevalence and mortality of sepsis-
associated ARDS, a prospective RCT investigating
glucocorticoid treatment is lacking. This is the first
randomized, double-blind, placebo-controlled trial
evaluating the efficacy of hydrocortisone treatment
in early sepsis-associated ARDS.
 Hydrocortisone administration for 7 days was
associated with improvement in oxygenation
parameters and LIS without achieving a significant
survival benefit. After hydrocortisone removal,
improvements in oxygenation and LIS were
maintained. With the exception of hyperglycemia,
we found no increased rate of adverse events.
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